Trial · NCT01962948
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01962948, Phase 1, Phase 2, Terminated, Fox Chase Cancer Center; results first posted 2022-06-24
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Trials, record NCT01962948. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01962948
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- NCT number
- NCT01962948
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Fox Chase Cancer Center
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Interventions
- paclitaxel, ganetespib, laboratory biomarker analysis
- First posted
- 2013-10-16
- Last updated
- 2024-03-26
- Results first posted
- 2022-06-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended Phase II Dose of Ganetespib With Weekly Paclitaxel, Based on the Incidence of Dose-limiting Toxicity (DLT) Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 (Phase I) | Up to 28 days | |
| Primary | Progression-free Survival at 6 Months (Phase II) | From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months | |
| Primary | Response Rate Defined as the Proportion of Patients With a Best Response of Complete Response (CR) or Partial Response (PR) Per RECIST v. 1.1 (Phase II) | Up to 4 years | |
| Secondary | Duration of Progression-free Survival (Phase II) | From start of treatment to time of progression or death, whichever occurs first, assessed up to 4 years |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Recommended Phase II Dose of Ganetespib With Weekly Paclitaxel, Based on the Incidence of Dose-limiting Toxicity (DLT) Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 (Phase I) | Up to 28 days | mg/m2 ganetespib | NUMBER | |
| PRIMARY | Progression-free Survival at 6 Months (Phase II) | From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months | The study was suspended prematurely due to halt in drug production and data were not analyzed | ||
| PRIMARY | Response Rate Defined as the Proportion of Patients With a Best Response of Complete Response (CR) or Partial Response (PR) Per RECIST v. 1.1 (Phase II) | Up to 4 years | The study was suspended prematurely due to halt in drug production and data were not analyzed | ||
| SECONDARY | Duration of Progression-free Survival (Phase II) | From start of treatment to time of progression or death, whichever occurs first, assessed up to 4 years | The study was suspended prematurely due to halt in drug production and data were not analyzed |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Recommended Phase II Dose of Ganetespib With Weekly Paclitaxel, Based on the Incidence of Dose-limiting Toxicity (DLT) Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 (Phase I) | Treatment (Paclitaxel, Ganetespib) | 150 | mg/m2 ganetespib |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 | |
| Overall Study | STARTED | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 | |
| Overall Study | STARTED | Phase 1: 150 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 6 | |
| Overall Study | STARTED | Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel | 0 | |
| Overall Study | COMPLETED | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 0 | |
| Overall Study | COMPLETED | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 0 | |
| Overall Study | COMPLETED | Phase 1: 150 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 0 | |
| Overall Study | COMPLETED | Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel | 0 | |
| Overall Study | NOT COMPLETED | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 | |
| Overall Study | NOT COMPLETED | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events264
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 2 | 3 | |
| other | Diarrhea | Gastrointestinal disorders | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 0 | 3 | |
| other | Diarrhea | Gastrointestinal disorders | Phase 1: 150 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 2 | 6 | |
| other | Diarrhea | Gastrointestinal disorders | Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel | 0 | 0 | |
| other | Nausea | Gastrointestinal disorders | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 1 | 3 | |
| other | Nausea | Gastrointestinal disorders | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 1 | 3 | |
| other | Nausea | Gastrointestinal disorders | Phase 1: 150 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 | 6 | |
| other | Nausea | Gastrointestinal disorders | Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel | 0 | 0 | |
| other | Constipation | Gastrointestinal disorders | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 2 | 3 | |
| other | Constipation | Gastrointestinal disorders | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 1 | 3 |
1 to 10 of 264Source ClinicalTrials.gov
See all 264 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 | 3 |
| Total, all-cause mortality | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 1 | 3 |
| Total, all-cause mortality | Phase 1: 150 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 4 | 6 |
| Total, all-cause mortality | Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel | 0 | 0 |
| Total, other adverse events | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 | 3 |
| Total, other adverse events | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 3 | 3 |
| Total, other adverse events | Phase 1: 150 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 6 | 6 |
| Total, other adverse events | Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel | 0 | 0 |
| Total, serious adverse events | Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 0 | 3 |
| Total, serious adverse events | Phase 1: 125 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel | 0 | 3 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | WIEST, DAVID L. | RESEARCH INST OF FOX CHASE CAN CTR | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01962948
GET https://conductscience.org/api/trials/v1/NCT01962948/events?page=2